Childhood-Onset Leber Hereditary Optic Neuropathy

Anna Majander, MD, PhD\textsuperscript{1,2,3}, Richard Bowman, MD, FRCOphth\textsuperscript{4}, Joanna Poulton, DM, FRCP\textsuperscript{5}, Richard J. Antcliff, MD, FRCOphth\textsuperscript{6}, M. Ashwin Reddy, MD, FRCOphth\textsuperscript{2}, Michel Michaelides, MD, FRCOphth\textsuperscript{1,2}, Andrew R. Webster, PhD, FRCOphth\textsuperscript{1,2}, Patrick F. Chinnery, PhD, FRCP\textsuperscript{7,8,9}, Marcela Votruba, PhD, FRCOphth\textsuperscript{10}, Anthony T. Moore, MD, FRCOphth\textsuperscript{1,2,11}, Patrick Yu-Wai-Man, PhD, FRCOphth\textsuperscript{1,2,7,12}

\textsuperscript{1}UCL Institute of Ophthalmology, London, UK
\textsuperscript{2}Moorfields Eye Hospital, London, UK
\textsuperscript{3}Department of Ophthalmology, Helsinki University Hospital, and University of Helsinki, Helsinki, Finland
\textsuperscript{4}Great Ormond Street Hospital, Great Ormond Street, London, UK.
\textsuperscript{5}Nuffield Department of Obstetrics & Gynaecology, University of Oxford, Oxford, UK
\textsuperscript{6}Department of Ophthalmology, Royal United Hospital, Bath, UK
\textsuperscript{7}Wellcome Trust Centre for Mitochondrial Research, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK.
\textsuperscript{8}Medical Research Council Mitochondrial Biology Unit, Cambridge, UK
\textsuperscript{9}Department of Clinical Neurosciences, School of Clinical Medicine, University of Cambridge, UK
\textsuperscript{10}School of Optometry and Vision Sciences, Cardiff University and Cardiff Eye Unit, University Hospital Wales, Cardiff, UK
\textsuperscript{11}Ophthalmology Department, UCSF School of Medicine, San Francisco, CA
\textsuperscript{12}Newcastle Eye Centre, Royal Victoria Infirmary, Newcastle upon Tyne, UK.

Corresponding Authors:
Anna Majander. E-mail: anna.majander@hus.fi

Total word count = 2804

Authors’ contributions:
Research design: AM, MV, ATM, PYWM

Data acquisition and/or research execution: AM, RB, JP, RJA, MAR, MM, ARW, MV, ATM, PYWM

Data analysis and/or interpretation: AM, PFC, MV, ATM, PYWM

Manuscript preparation: AM, PYWM

Disclosures

PYWM holds a consultancy agreement with GenSight Biologics (Paris, France).

Funding:

This research was supported by the National Institute for Health Research Rare Diseases Translational Research Collaboration (NIHR RD-TRC) and the National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital National Health Service Foundation Trust and UCL Institute of Ophthalmology, the NIHR Moorfields Clinical Research Facility. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

AM receives funding from Suomen Silmätutkimusseura ry:n Apurahasäätiö (Finland). MV and PYWM receive funding from Fight for Sight (UK). ATM, MV, PFC and PYWM receive funding from the UK National Institute of Health Research (NIHR) as part of the Rare Diseases Translational Research Collaboration. PYWM is supported by a Clinician Scientist Fellowship Award (G1002570) from the Medical Research Council (UK). PFC is a Wellcome Trust Senior Fellow in Clinical Science (101876/Z/13/Z), and a UK NIHR Senior Investigator, who receives support from the Medical Research Council Mitochondrial Biology Unit (MC_UP_1501/2), the Wellcome Trust Centre for Mitochondrial Research (096919Z/11/Z), the Medical Research Council (UK) Centre for Translational Muscle Disease (G0601943). JP was funded by the MRC (MR/J010448/1) and the Wellcome Trust
and has salary support from the NHS Specialized Services Rare Mitochondrial Disorders Service.

**Keywords:** Childhood; Leber hereditary optic neuropathy (LHON); mitochondrial disease; visual prognosis; optic atrophy.
Abstract

Background:
The onset of Leber hereditary optic neuropathy (LHON) is relatively rare in childhood. This study describes the clinical and molecular genetic features observed in this specific LHON subgroup.

Methods:
Our retrospective study consisted of a UK paediatric LHON cohort of 27 patients and 69 additional cases identified from a systematic review of the literature. Patients were included if visual loss occurred at the age of 12 years old or younger with a confirmed pathogenic mitochondrial DNA mutation: m.3460G>A, m.11778G>A, or m.14484T>C.

Results:
In the UK paediatric LHON cohort, 3 patterns of visual loss and progression were observed: (i) classical acute (17/27, 63%); (ii) slowly progressive (4/27, 15%); and (iii) insidious or subclinical (6/27, 22%). Diagnostic delays of 3-15 years occurred in children with an insidious mode of onset. Spontaneous visual recovery was more common in patients carrying the m.3460G>A and m.14484T>C mutations compared with the m.11778G>A mutation. Based a meta-analysis of 67 patients with available visual acuity data, 26 (39%) patients achieved a final best-corrected visual acuity (BCVA) $\geq 0.5$ Snellen decimal in at least one eye, whereas 13 (19%) patients had a final BCVA $< 0.05$ in their better seeing eye.

Conclusion:
Although childhood-onset LHON carries a relatively better visual prognosis, approximately 1 in 5 patients will remain within the visual acuity criteria for legal blindness in the UK. The clinical presentation can be insidious and LHON should be considered in the differential diagnosis when faced with a child with unexplained subnormal vision and optic disc pallor.
Word count: 250
Synopsis

Childhood-onset Leber hereditary optic neuropathy (LHON) carries a relatively better visual prognosis. Patients can present atypically with an insidious/subclinical course and LHON should be considered in children with unexplained subnormal vision and optic disc pallor.

Word count: 35
Introduction

Leber hereditary optic neuropathy (LHON) (OMIM 535000) is a mitochondrial disorder that classically presents with acute or subacute bilateral loss of central vision in young adult men.[1-3] About 90% of patients carry one of the three major disease causing LHON mitochondrial DNA (mtDNA) mutations (\textit{MTND}1 m.3460G>A, \textit{MTND}4 m.11778G>A and \textit{MTND}6 m.14484T>C), all of which encode for critical complex I subunits of the mitochondrial respiratory chain.[4] The greater availability of molecular genetic testing has broadened the phenotypic spectrum associated with LHON to include patients with more slowly progressive visual deterioration exceeding 6 months in duration, and those with an insidious/subclinical course characterised by the incidental discovery of subnormal vision and optic atrophy in the absence of overt visual symptoms.[1, 5] Although disease conversion can occur anywhere from the first to the eight decade of life, the peak age of onset of visual loss among LHON carriers is 20-30 years old.[1, 4] Childhood-onset disease is relatively rare and less than 10% of patients were 12 years old or younger at the time of diagnosis in previously published case series.[1, 6-10] Although there is limited data on this important patient subgroup, the phenotype seems distinct from classical adult-onset LHON with atypical patterns of vision loss and a better visual prognosis as reported in a previously published study of 18 patients with childhood-onset LHON.[7]

The aim of our study was to describe the clinical and molecular genetic characteristics associated with childhood-onset LHON, in particular the disease course and visual prognosis to better inform genetic counselling. We retrieved data for all eligible LHON patients that were seen at three major diagnostic centres for inherited optic neuropathies in the United Kingdom (UK). This UK paediatric LHON cohort was then combined with additional cases identified from a systematic review of the literature to generate a comprehensive meta-analysis of childhood LHON.
Patients and Methods

Study Population

This is a retrospective observational study approved by the local ethics committee at Moorfields Eye Hospital and it conformed to the standards set by the Declaration of Helsinki. LHON patients with disease onset at the age of 12 years old or younger were identified from the clinical and genetic data bases of the three main national diagnostic centres for inherited optic neuropathies in the UK (London, Oxford and Newcastle upon Tyne). We only included patients who carried one of the three canonical pathogenic mtDNA mutations, i.e., m.3460G>A, m.11778G>A and m.14484T>C.

Additional clinical information where relevant were sought from the original referring clinicians. Best corrected visual acuity (BCVA) at disease onset, at the nadir and at the last follow-up clinic visit were recorded. Patients were sub-classified into three groups based on the mode of onset and progression of visual loss: (i) acute, if visual acuity deteriorated rapidly reaching the nadir within 6 months from disease onset; (ii) slowly progressive, if visual deterioration occurred over a period exceeding 6 months; and (iii) insidious or subclinical, if the patient was clinically asymptomatic at the time that a diagnosis of optic atrophy or subnormal vision was made, and there was no change in visual acuity during subsequent follow-ups.[1, 7] Spontaneous visual recovery was defined as an improvement of BCVA by two lines or more on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart or from off-chart to on-chart visual acuity (0.05 Snellen decimal). A binocular visual acuity of at least 0.5 (6/12) is the minimum standard for driving in the UK [https://www.gov.uk/driving-eyesight-rules, accessed on 8 November 2016] and below 0.05 (3/60) is the legal definition of registrable blindness in the UK [https://www.gov.uk/government/publications/guidance-published-on-registering-a-vision-impairment-as-a-disability, accessed on 8 November 2016].

When available, spectral-domain optical coherence tomography (SD-OCT) data was retrieved from the database of the Spectralis™ (Heidelberg Engineering Ltd., Heidelberg, Germany) and Cirrus...
HD-OCT 4000™ (Carl Zeiss Meditec, Inc., Dublin, CA, USA) platforms, and compared with the normative data described elsewhere.[11, 12]

Systematic Literature Review

A comprehensive literature search was conducted using the search terms “LHON”, “Leber hereditary optic neuropathy” or “Leber’s hereditary optic neuropathy” and “child”, “childhood”, “paediatric” or “paediatric” on PubMed (https://www.ncbi.nlm.nih.gov/pubmed/, accessed on 8 November 2016). We also reviewed all the papers that included previously published publications on childhood LHON in their reference lists. A LHON patient was included in our meta-analysis only if there was confirmation of the m.3460G>A, m.11778G>A, or m.14484T>C mtDNA mutation, and disease onset was clearly stated as being before the age of 12 years old or younger. None of the patients included in the historical case series was present in the UK paediatric LHON cohort. Due to the retrospective nature of our systematic literature review, more detailed clinical information regarding visual acuity and disease progression was not available for 29 of the 69 eligible patients included in our historical case series.

Statistical Analysis

The Kruskal-Wallis test and Mann-Whitney U independent samples test were used for comparing the age at onset between the LHON genotypes and the distribution of retinal layer thickness in LHON and control eyes, respectively. The Spearman’s rank correlation test was used to assess for the strength of dependence between BCVA and retinal layer thickness (IBM Statistical Package of Social Sciences (SPSS) 22 v100).

Results
The UK paediatric LHON cohort included 27 patients who were 2 to 11 years old (mean = 6.9 years, standard deviation (SD) = 2.9 years) at the time of onset of visual loss or when subnormal visual acuity or optic disc pallor first became apparent (Table 1). Thirteen patients (48%) carried the m.11778G>A mutation, 7 patients (26%) the m.3460G>A mutation, and 7 patients (26%) the m.14484T>C mutation (Table 2). Patients 24-27 belonged to the same family and out of 5 affected family members, 4 of them developed visual loss before the age of 6 years old. There was a known family history of LHON in 19 probands (70%). The male:female ratio varied between 2.5 to 3.3 for the 3 primary LHON mtDNA mutations with an overall male:female ratio of 3.0. There was no statistically significant difference in the age of disease onset between the LHON genotypes (Kruskal-Wallis test, p=0.831).

The majority of patients (17/27, 63%) experienced acute or subacute visual loss with the nadir being reached within 6 months of first disease onset. This mode of presentation was the most common in children harbouring the m.3460G>A mutation (6/7, 86%). In 4 patients (15%), visual acuity deteriorated slowly over a period extending up to 2 years. Three patients in this subgroup carried the m.14484T>C mutation and one the m.11778G>A mutation. There was an unexpectedly large number of children (6/27, 22%) with insidious or subclinical vision loss in the UK paediatric LHON cohort. Subnormal vision or optic disc pallor were detected during the first 2 years of life (n=4) or after failing the preschool visual screening assessment (n=2), which is mandatory in the UK for all 4-5 year olds (Table 1). None of these children demonstrated or were suspected of having impaired visual performance during their early years and no visual deterioration occurred on subsequent follow-up. Molecular genetic confirmation of LHON in this insidious/subclinical group was markedly delayed between 3 to 15 years due to the atypical presentation.

The mean final BCVA in the whole group of patients with childhood-onset LHON was 0.39 Snellen decimal (SD = 0.38, range = light perception – 1.2 Snellen decimal, median = 0.25) with a
mean disease duration of 18 years (SD = 16 years, range = 1 - 56 years, median = 16 years). BCVA
was ≥ 0.5 in 20/54 (37%) eyes and 14/27 (52%) patients had at least one eye with BCVA ≥ 0.5.
Conversely, BCVA was < 0.05 in 11/54 (20%) eyes and 5/27 (19%) patients met the legal definition of
blindness with a BCVA < 0.05 in their better seeing eye. The m.11778G>A mutation was associated
with a worse visual outcome compared with the m.3460G>A and m.14484T>C mutations (Table 2,
Figure 1). Ten (37%) patients had asymmetric final BCVA with a difference ≥ 2 lines on the ETDRS
chart, and this was associated with: (i) asymmetric visual loss in the acute stage (n = 2); (ii)
asymmetric visual recovery following an acute disease onset (n = 2); (iii) slowly progressive visual
loss (n = 3); and (iv) an insidious/subclinical course (n = 3). Patient 26, who harboured the
m.14484T>C mutation, presented with slowly progressive visual deterioration in only one eye. In
patients presenting with acute LHON, spontaneous visual recovery occurred in 20/34 (59%) eyes and
16 (80%) of the recovered eyes achieved a BCVA ≥ 0.5. The mean time to recovery was 29 months
(SD = 18 months, range = 9 – 60 months) and there was no significant differences between mutation
subgroups (m.3460G>A, mean = 28 months; m.11778G>A, mean = 27 months; m.14484T>C, mean =
32 months; Kruskal-Wallis test, p=0.958). Visual outcome was bimodal in the acute LHON group with
a BCVA ≥ 0.5 in 17/34 (50%) eyes and < 0.05 in 10/34 (29%) eyes (Figure 2). The majority of eyes for
patients classified as having slowly progressive (5/8, 63%) or insidious/subclinical (11/12, 82%) LHON
had BCVA < 0.5.
SD-OCT imaging of the optic nerve head was available for 26 eyes of 13 patients. There was a
significant reduction in the average peripapillary retinal nerve fibre layer (RNFL) thickness ranging
from 49.0% to 58.4% compared with control values. On subgroup analysis, there was no significant
correlation between BCVA and peripapillary RNFL thickness in any of the individual quadrants (data
not shown). Perifoveal volumetric retinal SD-OCT scans were available for 10 eyes of 5 patients.
Retinal thickness was significantly reduced in the LHON group (mean ± SD = 295.5 ± 17.7 µm)
compared with normal controls (mean ± SD = 340.8 ± 13.3 µm, Mann-Whitney U test p < 0.001). This
was specifically due to marked thinning of the GCL-IPL complex in the LHON group (mean ± SD = 43.2
± 2.9 μm) compared with normal controls (mean ± SD = 93.5 ± 7.8 μm, Mann-Whitney U test p < 0.001). There was a statistically significant correlation between BCVA and the remaining ganglion cell layer-inner plexiform layer (GCL-IPL) thickness (Spearman \rho =-0.773, p=0.009, Supplementary Figure 1).

Meta-Analysis of Childhood-Onset LHON

Our systematic review of the literature identified 69 LHON patients with onset of vision loss at the age of 12 years old or younger (mean = 8.5 years, median = 8.0 years, range = 3 - 12 years) from 20 original publications covering diverse populations: Australia, Brazil, Chile, China, Finland, France, Germany, Italy, Saudi Arabia, Switzerland, the UK, and the USA (Supplementary Table 1). [Supplementary appendix] The m.11778G>A mutation accounted for 47/69 (69%) of all the included cases. Visual acuity data was available for 40 patients and overall, 18/79 (23%) eyes achieved a BCVA ≥ 0.5 whereas 18/79 (23%) eyes achieved a BCVA < 0.05. We merged the UK paediatric and historical LHON cohorts to generate a meta-analysis of childhood-onset LHON (Supplementary Table 2, Supplementary Figure 2). The number of patients with a BCVA ≥ 0.5 in at least one eye was 26/67 (39%) whereas the number of patients with a BCVA < 0.05 in their better seeing eye was 13/67 (19%).

Discussion

LHON is a disease of young adults and due to its relative rarity, there is limited data on the clinical features and visual prognosis of childhood LHON. In this study, we first identified a UK paediatric LHON cohort consisting of 27 patients diagnosed before the age of 12 years old, which was then combined with a historical cohort of 69 eligible patients from 20 previously published reports.
(Supplementary Appendix). These two cohorts had similar clinical and molecular genetics profile and we therefore combined the data to generate a meta-analysis for a more comprehensive comparison with classical adult-onset LHON.

The distribution of the three major disease causing LHON mutations (m.3460G>A = 19%, m.11778G>A = 62.5%, and m.14484T>C = 19%) in the childhood cohort is comparable with previously reported adult LHON case series with the m.11778G>A mtDNA mutation being the most common genotype. As expected, there was a male preponderance, but the overall male:female ratio of 1.8 is less marked than the 4-5 fold increased risk of visual loss seen among adult male carriers.[13-14] The mechanisms contributing to this rather intriguing male bias are not fully understood and a number of secondary genetic, hormonal and environmental risk factors have been implicated.[15] Smoking and to a lesser extent heavy drinking are regarded as important environmental triggers, but these factors are unlikely to be aetiologically important in young children. Although this hypothesis needs to be formally verified, the less pronounced sex bias in childhood LHON could arise because it is more heavily genetically determined by nuclear modifiers, which contribute to an earlier age of onset, but that are less sex determined or influenced. The other phenotypic extreme would be late-onset adult cases over the age of 50 years old where environmental risk factors, in particular smoking, are thought to play a more prominent role in precipitating disease conversion.[16-17] A systematic genomic comparison of childhood LHON, classical acute cases in young adults and late-onset LHON could therefore prove the key to dissecting the complex genetic-environmental modulators that contribute to visual loss in different groups of susceptible carriers.

The classical acute pattern of vision loss was the most common presentation in childhood LHON, but over one third of patients either had a slowly progressive onset or even more strikingly, a subclinical or insidious disease evolution. In a previous report of 14 children with LHON from Barboni and colleagues, the 6 patients classified as having a slowly progressive course achieved better final
visual acuities compared with the acute group.[7] In contrast with this finding, the 4 patients in the
UK paediatric LHON cohort did not have a better prognosis, with the vision deteriorating in the
majority of eyes to less than the driving standards, i.e., BCVA < 0.5. The insidious/subclinical LHON
subgroup was observed with all 3 major disease causing mtDNA mutations and the defining
observation was the significant delays in reaching a confirmed molecular diagnosis, which ranged
from 3 to 15 years. Visually asymptomatic children in whom subnormal vision and optic atrophy,
which can be subtle, are detected incidentally have been reported previously and the diagnostic
challenges are likely to be multifactorial.[10, 18] Visual performance in this age group is not always
impaired due to the inherent adaptive capacity of young children and importantly, they may not be
able to communicate changes in their vision effectively to their parents or guardians. A lack of
clinical awareness of LHON in young children is also likely to be relevant in explaining the diagnostic
delays in this patient group.

LHON has a major impact on quality of life and the majority of patients will remain within
the criteria for legally blindness.[19] The observed overall rates of spontaneous visual recovery of
37% for all eyes in the entire UK paediatric LHON cohort and of 59% for the eyes of patients with
acute LHON, are in line with the corresponding values of 28% and 63% reported by Barboni and
colleagues.[7] Adult-onset LHON patients harbouring the m.14484T>C mutation have the best visual
prognosis with a partial visual recovery rate of 37-58% compared with 4-25% for the m.11778G>A
mutation, and 22-25% for the m.3460G>A mutation.[6, 8, 20-22] The variations in the reported rates
of spontaneous visual recovery reflect possible sampling bias depending on the cohort size and the
different criteria used to define a visually significant change in visual acuity from the nadir.[3] In our
study, the rates of spontaneous visual recovery were 57%, 23% and 43% for the m.3460G>A,
m.11778G>A and m.14484T>C mutations, respectively. Children carrying the m.3460G>A mutation
therefore seem to have a better visual prognosis, and the recovery rate observed with the
m.11778G>A mutation is also higher, compared with the clinical impression in patients with adult-
onset LHON.[6, 21] Based on our meta-analysis of 67 patients for whom visual acuity data was
available, 39% of patients achieved a BCVA ≥ 0.5 in at least one eye whereas 19% of patients had a BCVA < 0.05 in their better seeing eye. A more favourable final visual outcome was observed for all three genotypes in our childhood-onset LHON cohort compared with previously published figures (m.3460G>A: 14% versus 55-96%; m.11778G>A: 45% versus 73-98%; and m.14484T>C mutation: 6% versus 30-50% of eyes achieving a BCVA < 0.1).[1, 6, 8, 20-21] Mitochondrial turnover is implicated in the pathogenesis of LHON, both mitochondrial biogenesis and mitophagy being increased in fibroblasts of LHON patients.[23-24] The known age-related decline in mitophagy, and hence presumably mitochondrial biogenesis, may underlie this difference from adult disease.[25]

In conclusion, childhood-onset LHON represents a distinct phenotypic subgroup characterised by a more varied clinical evolution and a more favourable visual prognosis compared with classical adult LHON. Importantly, children do not always develop acute or subacute visual symptoms and a high index of suspicion is required in children presenting with unexplained subnormal vision and optic disc pallor to avoid potentially long diagnostic delays.
References


**Table 1.** Demographics and clinical features of patients included in the UK paediatric LHON cohort.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Mutation</th>
<th>Family history</th>
<th>f/m</th>
<th>Age at onset (y)</th>
<th>Mode of onset</th>
<th>Disease progression</th>
<th>Final BCVA(^{\wedge})</th>
<th>Time from onset (y)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>11778</td>
<td>yes</td>
<td>f</td>
<td>6</td>
<td>S</td>
<td>Gradual visual deterioration over 2 years.</td>
<td>0.17</td>
<td>47</td>
</tr>
<tr>
<td>2</td>
<td>11778</td>
<td>yes</td>
<td>f</td>
<td>8</td>
<td>A</td>
<td>No recovery</td>
<td>LP</td>
<td>56</td>
</tr>
<tr>
<td>3</td>
<td>11778</td>
<td>yes</td>
<td>f</td>
<td>9</td>
<td>A</td>
<td>No recovery</td>
<td>0.03</td>
<td>38</td>
</tr>
<tr>
<td>4</td>
<td>11778</td>
<td>yes</td>
<td>m</td>
<td>11</td>
<td>A</td>
<td>Worst BCVA: HM BE. Recovery within 12 months from onset.</td>
<td>0.76</td>
<td>1</td>
</tr>
<tr>
<td>5</td>
<td>11778</td>
<td>no</td>
<td>m</td>
<td>8</td>
<td>A</td>
<td>No recovery</td>
<td>CF</td>
<td>33</td>
</tr>
<tr>
<td>6</td>
<td>11778</td>
<td>no</td>
<td>m</td>
<td>3</td>
<td>I</td>
<td>Subnormal vision since birth.</td>
<td>0.17</td>
<td>52</td>
</tr>
<tr>
<td>7</td>
<td>11778</td>
<td>no</td>
<td>m</td>
<td>9</td>
<td>A</td>
<td>Worst BCVA: 0.08 RE, 0.4 LE. Asymmetric.</td>
<td>0.10</td>
<td>18</td>
</tr>
<tr>
<td>8</td>
<td>11778</td>
<td>yes</td>
<td>m</td>
<td>11</td>
<td>A</td>
<td>No recovery</td>
<td>0.07</td>
<td>2</td>
</tr>
<tr>
<td>9</td>
<td>11778</td>
<td>no</td>
<td>m</td>
<td>2</td>
<td>I</td>
<td>Subnormal vision detected when 2 years old. LHON diagnosed at the age of 8 yrs.</td>
<td>0.25</td>
<td>17</td>
</tr>
<tr>
<td>10</td>
<td>11778</td>
<td>yes</td>
<td>m</td>
<td>8</td>
<td>A</td>
<td>No recovery</td>
<td>CF</td>
<td>10</td>
</tr>
<tr>
<td>11</td>
<td>11778</td>
<td>no</td>
<td>m</td>
<td>10</td>
<td>A</td>
<td>Worst BCVA: CF BE. Recovery within 24 months from onset. Asymmetric recovery.</td>
<td>0.08</td>
<td>7</td>
</tr>
<tr>
<td>12</td>
<td>11778</td>
<td>yes</td>
<td>m</td>
<td>2</td>
<td>I</td>
<td>Subnormal vision detected when 2 years old. LHON diagnosed at the age of 6 yrs with BCVA of 0.18 RE and 0.17 LE. Slow visual recovery until 10 yrs old.</td>
<td>0.35</td>
<td>4</td>
</tr>
<tr>
<td>13</td>
<td>11778</td>
<td>yes</td>
<td>m</td>
<td>2</td>
<td>I</td>
<td>Optic atrophy noted at the age of 2 years. LHON diagnosed at the age of 17 years.</td>
<td>0.40</td>
<td>15</td>
</tr>
<tr>
<td>14</td>
<td>3460</td>
<td>yes</td>
<td>f</td>
<td>7</td>
<td>A</td>
<td>Worst BCVA: 0.05 BE. Recovery within 4 yrs from onset.</td>
<td>0.79</td>
<td>4.5</td>
</tr>
<tr>
<td>No.</td>
<td>ID</td>
<td>Sex</td>
<td>Age</td>
<td>Sex</td>
<td>Acuity</td>
<td>Details</td>
<td>BCVA 1</td>
<td>BCVA 2</td>
</tr>
<tr>
<td>-----</td>
<td>--------</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
<td>-------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>--------</td>
<td>--------</td>
</tr>
<tr>
<td>15</td>
<td>3460</td>
<td>f</td>
<td>11</td>
<td>A</td>
<td>No recovery.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>3460</td>
<td>m</td>
<td>4</td>
<td>I</td>
<td>Poor visual acuity noticed at pre-school screening assessment.</td>
<td></td>
<td>0.17</td>
<td>0.17</td>
</tr>
<tr>
<td>17</td>
<td>3460</td>
<td>m</td>
<td>6</td>
<td>A</td>
<td>Asymmetric visual recovery.</td>
<td></td>
<td>0.67</td>
<td>0.25</td>
</tr>
<tr>
<td>18</td>
<td>3460</td>
<td>m</td>
<td>8</td>
<td>A</td>
<td>Worst BCVA: 0.05 BE. Recovery within 12 months from onset.</td>
<td></td>
<td>1.20</td>
<td>1.20</td>
</tr>
<tr>
<td>19</td>
<td>3460</td>
<td>m</td>
<td>10</td>
<td>A</td>
<td>Worst BCVA: HM RE, CF LE. Recovery</td>
<td></td>
<td>0.33</td>
<td>0.50</td>
</tr>
<tr>
<td>20</td>
<td>3460</td>
<td>m</td>
<td>5</td>
<td>A</td>
<td>Worst BCVA: 0.1 BE. Recovery within 24 months from onset.</td>
<td></td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>21</td>
<td>14484</td>
<td>f</td>
<td>9</td>
<td>S</td>
<td>Gradual visual deterioration over 2 years.</td>
<td></td>
<td>0.17</td>
<td>0.25</td>
</tr>
<tr>
<td>22</td>
<td>14484</td>
<td>m</td>
<td>10</td>
<td>A</td>
<td>Recovery within 9 months from onset.</td>
<td></td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>23</td>
<td>14484</td>
<td>m</td>
<td>5</td>
<td>I</td>
<td>Poor visual acuity noticed at pre-school screening assessment.</td>
<td></td>
<td>0.25</td>
<td>0.25</td>
</tr>
<tr>
<td>24*</td>
<td>14484</td>
<td>f</td>
<td>6</td>
<td>A</td>
<td>Worst BCVA: 0.02 RE, 0.2 LE. Recovery within 5 yrs from onset.</td>
<td></td>
<td>0.91</td>
<td>1.00</td>
</tr>
<tr>
<td>25*</td>
<td>14484</td>
<td>m</td>
<td>6</td>
<td>S</td>
<td>Asymmetric visual recovery.</td>
<td></td>
<td>0.69</td>
<td>0.14</td>
</tr>
<tr>
<td>26*</td>
<td>14484</td>
<td>m</td>
<td>4</td>
<td>S</td>
<td>Slowly progressive visual deterioration in the left eye only.</td>
<td></td>
<td>1.00</td>
<td>0.10</td>
</tr>
<tr>
<td>27*</td>
<td>14484</td>
<td>m</td>
<td>5</td>
<td>A</td>
<td>Off-chart vision (BE) at the nadir. Asymmetric recovery within 2-3 yrs from onset.</td>
<td></td>
<td>0.07</td>
<td>0.67</td>
</tr>
</tbody>
</table>

* From the same pedigree. † Best-corrected visual acuity (BCVA) recorded at last follow-up clinic visit in Snellen decimal.
Abbreviations: A, acute; BCVA, best corrected visual acuity; BE, both eyes; CF, counting fingers at 0.25 metre; f, female; HM, hand movement; I, insidious; LE, left eye; m, male; RE, right eye; S, slowly progressive.
Table 2. Data summary of patients included in the UK paediatric LHON cohort.

<table>
<thead>
<tr>
<th>Mutation</th>
<th>Patients (pedigrees)</th>
<th>Sex</th>
<th>Age at onset (y)</th>
<th>Acute onset</th>
<th>Slowly progressive onset</th>
<th>Insidious / subclinical onset</th>
<th>Visual recovery *</th>
<th>BCVA ≥ 0.5</th>
<th>BCVA &lt; 0.05</th>
</tr>
</thead>
<tbody>
<tr>
<td>11778</td>
<td>13 (13)</td>
<td>3</td>
<td>10</td>
<td>6.8 (8)</td>
<td>8 (61)</td>
<td>1 (7)</td>
<td>4 (30)</td>
<td>6 (23)</td>
<td>0.20 (19)</td>
</tr>
<tr>
<td>3460</td>
<td>7 (7)</td>
<td>2</td>
<td>5</td>
<td>7.3 (7)</td>
<td>6 (86)</td>
<td>0</td>
<td>1 (14)</td>
<td>8 (57)</td>
<td>0.60 (57)</td>
</tr>
<tr>
<td>14484</td>
<td>7 (4)</td>
<td>2</td>
<td>5</td>
<td>6.4 (6)</td>
<td>3 (29)</td>
<td>3 (29)</td>
<td>1 (14)</td>
<td>6 (43)</td>
<td>0.54 (50)</td>
</tr>
<tr>
<td>All</td>
<td>27 (24)</td>
<td>7</td>
<td>21</td>
<td>6.9 (7)</td>
<td>17/27 (63)</td>
<td>4/27 (15)</td>
<td>6/27 (22)</td>
<td>20/54 (37)</td>
<td>0.39 (37)</td>
</tr>
</tbody>
</table>

* Number of eyes with visual recovery.

# Number of eyes with best-corrected visual acuity (BCVA) ≥ 0.5 or < 0.05 in Snellen decimal.

Abbreviations: BCVA, best corrected visual acuity; f, female; m, male.